TABLE 1.
Characteristics and Cardiac MRI Findings of Patients in Studies With Individual‐Level Patient Data
| Characteristics | Data Availability (n) | Findings | |
|---|---|---|---|
| Age (years), mean (SD) | 274 | 27.3 (14.1) | |
| Male, n (%) | 294 | 264 (89.8%) | |
| Survived, n (%) | 263 | 263 (100%) | |
| Vaccine type, n (%) | Pfizer (BNT162b2) | 294 | 213 (72.4%) |
| Moderna (mRNA‐1273) | 67 (22.8%) | ||
| Janssen (ad26.COV2.S) | 4 (1.4%) | ||
| AstraZeneca (chAdOx1‐SARS‐COV‐2) | 9 (3.1%) | ||
| Covaxin (BBV152) | 1 (0.3%) | ||
| Vaccine dose, n (%) | First dose | 293 | 54 (18.4%) |
| Second dose | 230 (78.2%) | ||
| Third dose | 9 (3.1%) | ||
| Time from vaccine to symptoms (day), median (IQR) | 282 | 3 (2.0 to 4.0) | |
| Symptom type, n (%) | Chest pain | 266 | 254 (95.4%) |
| Dyspnea | 58 (21.8%) | ||
| Abnormal ECG | 259 | 221 (85.3%) | |
| ST segment elevation | 198 | 150 (75.7%) | |
| Diffuse PR depression | 32 (16.1%) | ||
| Nonspecific ST‐T changes | 41 (20.7%) | ||
| Elevated troponin, n (%) | 278 | 276 (99.3%) | |
| Echocardiography findings | |||
| LVEF (%), mean (SD) | 137 | 53.70 (9.4) | |
| LVEF < 50%, n (%) | 137 | 34 (24.8%) | |
| LVEF < 55%, n (%) | 203 | 63 (31%) | |
| Pericardial effusion, n (%) | 95 | 7 (7.3%) | |
| Wall motion abnormality, n (%) | 113 | 49 (43.3%) | |
| Cardiac MRI findings | |||
| Time from vaccine to MRI (day), Median (IQR) | 68 | 6.0 (5 to 8.8) | |
| Lake louise criteria, n (%) | 114 | 99 (86.8%) | |
| Native T1 (msec), Mean (SD) | 73 | 1083.91 (94.3) | |
| Elevated T1, n (%) | 102 | 76 (74.5%) | |
| Native T2 (msec), Mean (SD) | 69 | 55.9 (9.5) | |
| Elevated Native T2, n (%) | 102 | 62 (60.8%) | |
| T2 weighted or T2 STIR or T2 mapping abnormality, n (%) | 160 | 131 (81.9%) | |
| Myocardial LGE, n (%) | |||
| Positive LGE | 285 | 268 (94%) | |
| LGE Pattern | |||
| Subepicardial + & Mid wall −, n (%) | 208 | 137 (65.9%) | |
| Subepicardial − & Mid wall +, n (%) | 23 (11.1%) | ||
| Subepicardial + & Mid wall +, n (%) | 46 (22.1%) | ||
| Subepicardial + | Mid wall +, n (%) | 206 (99.0%) | ||
| Subepicardial − & Mid wall −, n (%) | 2 (0.9%) | ||
| Subepicardial/Mixed LGE | 208 | 183 (88.0) | |
| Mid wall/Mixed LGE | 208 | 69 (33.2%) | |
| Nonischemic pattern of myocarditis, n (%) | 214 | 214 (100%) | |
| Involved segment, n (%) | |||
| Basal or mid inferolateral, n (%) | 202 | 124 (61.4%) | |
| Other segments, n (%) | 202 | 78 (38.6%) | |
| ECV (%), Mean (SD) | 50 | 29.61 (6.04) | |
| ECV > 30%, n (%) | 16 (32%) | ||
| LVEF (%), Mean (SD) | 155 | 56.7 (7.57) | |
| LVEF <55%, n (%) | 177 | 58 (32.8%) | |
| LVEF <50%, n (%) | 174 | 16 (9.2%) | |
| Wall motion abnormality, n (%) | 93 | 29 (31.2%) | |
| Pericardial enhancement, n (%) | 119 | 39 (32.8%) | |
| Pericardial effusion, n (%) | 147 | 40 (27.2%) | |
ECV = extracellular volume; ECG = electrocardiography; IQR = interquartile range; LGE = late gadolinium enhancement; LVEF = left ventricular ejection fraction; mRNA = messenger ribonucleic acid; N = number; SD = standard deviation; STIR = short‐tau inversion recovery.